ArticleDiscover oncology2026
Construction and evaluation of a bladder cancer prognosis model based on super-enhancer-associated genes.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionBladder cancer (BLCA) is a malignant tumour that occurs on the mucosa of the bladder. It accounts for the first place in the incidence of genitourinary tumours in China. BLCA is characterized by high recurrence rate and poor survival rate. There is still a research gap regarding super-enhancer-related genes (SERGs) in BLCA.
methodsThe The Cancer Genome Atlas Bladder Urothelial Carcinoma (TCGA-BLCA) and GSE31684 were subjected into this study. In addition, the Super-Enhancer Archive database was used to identify SERGs. Differential expression analysis was used to analyse the differentially expressed genes (DEGs) between the BLCA and control groups. The DEGs were overlapped with SERGs to get candidate genes in TCGA-BLCA, which were analyzed for Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). Univariate Cox, Least Absolute Shrinkage and Selection Operator (Lasso) regression and multivariate Cox regression analyses were used to build the risk model for BLCA. Survival analyses and validation of the model were performed by Kaplan-Meier (K-M) curves and Receiver Operating Characteristic (ROC) curve, respectively. In addition, using the estimating relative subsets of RNA transcripts (CIBERSORT) algorithm, 22 immune cell proportions were calculated. The drug sensitivity was also analyzed in this study.
resultsFirst of all, based on the TCGA-BLCA, 70 DE-SERGs were yielded. A prognosis model based on MXRA7, PLEKHG4B and ATP2B4 was finally constructed. ROC curves revealed that the prognosis model was a good predictor of BLCA outcomes. Immune infiltration analysis revealed that risk score was positively associated with T cells CD4 memory resting, Mast cells resting and Macrophages M2 and negatively associated with Dendritic cells activated and T cells CD8. Besides, AZD8186, BMS-754,807, JQ1, KRAS (G12C) Inhibitor and NU7441 were the top five sensitivity drugs for BLCA.
conclusionThree genes (MXRA7, PLEKHG4B and ATP2B4) were identified to construct a SERG-related model in BLCA, which provides a basis for understanding BLCA pathogenesis and new insights into BLCA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.